Novo Nordisk A/S : præsenterer 63 abstracts på diabeteskongressen ADA i San Francisco

 Liraglutide 3.0 mg for Weight Management in Obese/Overweight Adults with Type

2 Diabetes: Results from the SCALE™ Diabetes 56-Week Randomized, Double- blind, Placebo-controlled Trial (Abstract #97-OR)

 One-year Efficacy and Safety of IDegLira in Patients with Type 2 Diabetes

(Abstract #65-OR)
 Impact of BMI on HbA1c Reduction, Hypoglycaemia Rates and Insulin
Requirements in Response to IDegLira in Patients with Type 2 Diabetes (Abstract
#66-OR)

 IDegLira Efficacy Across the Range of Disease Progression in Type 2 Diabetes

(Abstract #0067-OR)

 Efficacy and Safety of Liraglutide versus Placebo as Add-on to Existing Diabetes Medication in Subjects with Type 2 Diabetes (T2DM) and Moderate Renal Impairment (Abstract #965-P)

 Efficacy and Safety of Liraglutide versus Placebo as Add-on to Existing Diabetes Medication in Subjects with Type 2 Diabetes (T2DM) and Moderate Renal Impairment (Abstract #331-OR)

 Rate Ratios for Nocturnal Confirmed Hypoglycaemia with Insulin Degludec vs.

Insulin Glargine Using Different Definitions (Abstract #402-P)
En komplet oversigt over abstracts kan ses her.

Corporate Communications

Novo Allé

2880 Bagsværd

Danmark

Telefon:

+45 4444 8888

Internet: www.novonordisk.com CVR-nr.:

24 25 67 90

Side 2 af 2

Corporate Communications

Novo Allé

2880 Bagsværd

Danmark

Telefon:

+45 4444 8888

Internet: www.novonordisk.com CVR-nr.:

24 25 67 90

distributed by